Jundishapur Journal of Microbiology

Published by: Kowsar

A Study on the Virus-Like Particle Formation of Hepatitis E Virus ORF2 and Rotavirus NSP4 Protein in the Eukaryotic and Prokaryotic Expression Systems

Manoochehr Makvandi 1 , Ali Teimoori 1 , 2 , Niloofar Neisi 1 , * and Alireza Samarbafzadeh 1
Authors Information
1 Infectious and Tropical Diseases Research Center, Health Research Institute, Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Research Center for Infectious Diseases of Digestive System, Imam Khomeini hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Article information
  • Jundishapur Journal of Microbiology: December 2017, 10 (12); e57671
  • Published Online: November 21, 2017
  • Article Type: Research Article
  • Received: August 9, 2017
  • Revised: October 6, 2017
  • Accepted: October 14, 2017
  • DOI: 10.5812/jjm.57671

To Cite: Makvandi M, Teimoori A, Neisi N, Samarbafzadeh A. A Study on the Virus-Like Particle Formation of Hepatitis E Virus ORF2 and Rotavirus NSP4 Protein in the Eukaryotic and Prokaryotic Expression Systems, Jundishapur J Microbiol. 2017 ; 10(12):e57671. doi: 10.5812/jjm.57671.

Copyright © 2017, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusions
  • 1. Li S, Zhang J, Xia N. Lessons from hepatitis E vaccine design. Curr Opin Virol. 2015; 11: 130-6[DOI][PubMed]
  • 2. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine. 2004; 22(3-4): 370-7[DOI][PubMed]
  • 3. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11(9): 438-44[DOI][PubMed]
  • 4. Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013; 31(11): 654-63[DOI][PubMed]
  • 5. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012; 31(1): 58-83[DOI][PubMed]
  • 6. Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H, et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol. 2005; 79(20): 12999-3006[DOI][PubMed]
  • 7. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res. 2011; 161(1): 93-100[DOI][PubMed]
  • 8. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007; 25(19): 3752-62[DOI][PubMed]
  • 9. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin. 2008; 4(5): 347-9[DOI][PubMed]
  • 10. Gupta RK, Siber GR. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine. 1995; 13(14): 1263-76[DOI][PubMed]
  • 11. Kavanagh OV, Ajami NJ, Cheng E, Ciarlet M, Guerrero RA, Zeng CQ, et al. Rotavirus enterotoxin NSP4 has mucosal adjuvant properties. Vaccine. 2010; 28(18): 3106-11[DOI][PubMed]
  • 12. Ball JM, Mitchell DM, Gibbons TF, Parr RD. Rotavirus NSP4: a multifunctional viral enterotoxin. Viral Immunol. 2005; 18(1): 27-40[DOI][PubMed]
  • 13. Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine. 2009; 27(12): 1869-74[DOI][PubMed]
  • 14. Makvandi M, Teimoori A, Neisi N, Samarbafzadeh A. Designing, Construction and Expression of a Recombinant Fusion Protein Comprising the Hepatitis E Virus ORF2 and Rotavirus NSP4 in the Baculovirus Expression System. Jundishapur J Microbiol. 2016; 9(11)[DOI][PubMed]
  • 15. Oliver S. Proteins and proteomics: A laboratory manual. Nature. 2003; 422(6931): 473[DOI]
  • 16. Li SW, Zhang J, He ZQ, Gu Y, Liu RS, Lin J, et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem. 2005; 280(5): 3400-6[DOI][PubMed]
  • 17. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol. 2009; 655: 145-58[DOI][PubMed]
  • 18. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82(5): 488-96[DOI][PubMed]
  • 19. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine. 2003; 21 Suppl 2-95[DOI][PubMed]
  • 20. Zhang M, Zeng CQ, Dong Y, Ball JM, Saif LJ, Morris AP, et al. Mutations in rotavirus nonstructural glycoprotein NSP4 are associated with altered virus virulence. J Virol. 1998; 72(5): 3666-72[PubMed]
  • 21. Niikura M, Takamura S, Kim G, Kawai S, Saijo M, Morikawa S, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology. 2002; 293(2): 273-80[DOI][PubMed]
  • 22. Jariyapong P, Xing L, van Houten NE, Li TC, Weerachatyanukul W, Hsieh B, et al. Chimeric hepatitis E virus-like particle as a carrier for oral-delivery. Vaccine. 2013; 31(2): 417-24[DOI][PubMed]
  • 23. Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine. 2001; 19(25-26): 3476-84[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments